Juno ends flagship drug trial after deaths and FDA suspensions
March 01, 2017 at 17:52 PM EST
“We … recognize the unfortunate and unexpected toxicity we saw in our trial," Juno Therapeutics CEO Hans Bishop said.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.